CE-158

CE-158
	File:CE-158.svg
Clinical data
Other names	(S,S)-CE-158; S,S-CE-158
Drug class	Atypical dopamine reuptake inhibitor
Identifiers
	IUPAC name 5-(3-bromophenyl)-phenylmethyl sulfinylmethyl-1,3-thiazole;
CAS Number	2621388-55-2 check;
PubChem CID	156150588;
E number	{{#property:P628}}
CompTox Dashboard (EPA)	{{#property:P3117}}Lua error in Module:EditAtWikidata at line 29: attempt to index field 'wikibase' (a nil value).;
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 29: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C17H14BrNOS2
Molar mass	392.33 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C1=CC=C(C=C1)C(C2=CC(=CC=C2)Br)S(=O)CC3=CN=CS3;
	InChI InChI=1S/C17H14BrNOS2/c18-15-8-4-7-14(9-15)17(13-5-2-1-3-6-13)22(20)11-16-10-19-12-21-16/h1-10,12,17H,11H2; Key:KWWHBBCVAQTAFQ-UHFFFAOYSA-N;

CE-158 is an atypical dopamine reuptake inhibitor (DRI) that was derived from modafinil.^[1]^[2]^[3]^[4]^[5] It is often but not always referred to as the enantiopure enantiomer (S,S)-CE-158 instead.^[2]^[3]^[5]

CE-158 is a highly selective DRI with much greater potency than modafinil.^[3]^[5] As (S,S)-CE-158, its inhibitory potencies (IC₅₀Tooltip half-maximal inhibitory concentration) at the monoamine transporters are 227 nM at the dopamine transporter (DAT), 11,970 nM at the norepinephrine transporter (NET) (53-fold lower), and inactive at the serotonin transporter (SERT).^[5]

The drug shows pro-motivational effects in animals and reverses tetrabenazine-induced motivational deficits.^[1] It increases dopamine levels in the nucleus accumbens, blocks amphetamine-induced dopamine release in vitro, shows no effect on locomotor activity with acute or repeated administration except at a high dose, and enhances learning in animals.^[3]^[2]^[5]

CE-158 was first described by 2020.^[5] It is closely related to CE-123, an earlier modafinil analogue.^[4]^[5] CE-158 and related agents are of interest in the potential treatment of motivational disorders, psychostimulant use disorder (PSUD), and Alzheimer's disease.^[1]^[2]^[3]^[4]^[5]

References

^ ^a ^b ^c Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
^ ^a ^b ^c ^d Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
^ ^a ^b ^c ^d ^e Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
^ ^a ^b ^c Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
^ ^a ^b ^c ^d ^e ^f ^g ^h Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).